Federal support for Kardium
The Canadian government has earmarked a $31.25‑million injection for Kardium Inc., a Burnaby‑based developer of medical devices for atrial fibrillation. The funding comes from the Strategic Response Fund, a programme designed to accelerate biomanufacturing and life‑sciences projects across the country. Kardium will use the capital to finance a larger portion of a $125‑million investment that will more than double its clean‑room space from 10,000 to 25,000 square feet. The move is intended to give the company greater control over its manufacturing chain, a priority for a firm that aims to become a globally independent player.
The announcement follows regulatory approvals that have opened new markets for the device. The U.S. Food and Drug Administration cleared the catheter in August 2025, and Health Canada granted its own clearance last month. Those decisions have positioned Kardium to expand sales beyond Canada, while the government’s financial backing helps it meet the scaling challenges that come with larger production volumes.
Scaling up clean‑room production
Kardium’s catheter is a sophisticated instrument that navigates the femoral vein to reach the heart. Once in place, the device expands into a three‑centimetre‑wide globe that acts like a disco ball, pinpointing the source of erratic electrical signals and delivering targeted therapy. Clinical trials have shown superior outcomes compared with competing technologies, giving the company a strong commercial foothold.
Manufacturing such precision equipment demands stringent environmental controls. Each clean room must be free of dust, germs and airborne contaminants, and is equipped with dedicated heating, ventilation and air‑conditioning systems. The current 10,000‑square‑foot footprint is already the site of a substantial workforce: more than 700 employees, with an additional 200 recruited this year for production roles. The expansion will not only increase output capacity but also create new skilled jobs in the Greater Vancouver area, reinforcing the region’s reputation as a hub for advanced medical‑device manufacturing.
Chief Executive Kevin Chaplin emphasised the strategic importance of controlling the manufacturing process. “We’re building Kardium to be an independent company and in order to do that we want to have control of our own destiny. That means controlling our own manufacturing,” he said in an interview. The company’s long‑term vision includes opening a second facility in Costa Rica by 2029, a nation recognised as a major centre for medical‑device production. That overseas site is expected to eventually supply the majority of global demand, allowing the Burnaby plant to focus on North American and regional markets.
Global manufacturing strategy
Kardium’s growth trajectory is underpinned by a blend of public and private financing. While the federal grant covers a modest portion of the overall investment, the firm has attracted nearly $500‑million from a roster of international investors, including Fidelity, T. Rowe Price Associates and Qatar’s sovereign wealth fund. The company, which celebrates its 19th anniversary this year, is preparing for an initial public offering as early as the second half of 2027, a move that will provide additional capital for further expansion.
The Strategic Response Fund has been a consistent source of support for British Columbia’s life‑sciences sector. Kardium’s award marks the eighth commitment to B.C. projects under the fund, which has disbursed 35 grants nationwide for biomanufacturing and life‑sciences initiatives. Recent B.C. recipients include Aspect Biosystems, which 3‑D prints live tissue implants, and a new incubator at Providence Health Care. Past investments have also benefitted Vancouver‑based Stemcell Technologies Canada Inc. and AbCellera Biologics, the latter receiving $400‑million in total, split between a 2020 COVID‑19 antibody grant and a 2023 allocation for hot‑flash treatment development.
AbCellera’s recent efficacy trial success has already triggered a $200‑million fundraising round, underscoring the ripple effect of government‑backed programmes in attracting private capital. The pattern of support demonstrates a coordinated effort to position Canada, and British Columbia in particular, as a competitive destination for cutting‑edge medical‑device and biotech ventures.
Impact on British Columbia’s biotech sector
The Kardium investment is more than a financial transaction; it signals confidence in Canada’s ability to nurture home‑grown innovation in cardiovascular medicine. By expanding its clean‑room infrastructure, the company not only enhances its own production capabilities but also contributes to the region’s skilled workforce and supply‑chain ecosystem. The additional 200 manufacturing jobs add to the growing talent pool in the province’s life‑sciences landscape.
Moreover, the project aligns with broader governmental objectives to reduce reliance on foreign manufacturing and to retain high‑value jobs within North America. The Strategic Response Fund’s focus on biomanufacturing reflects a strategic response to global supply‑chain vulnerabilities exposed in recent years. Kardium’s dual‑site approach—maintaining a North American hub while leveraging cost‑effective production abroad—exemplifies a balanced model that can be replicated by other emerging Canadian firms.
The company’s forthcoming public listing is expected to further integrate Kardium into Canadian capital markets, offering domestic investors a stake in a firm that competes on the world stage. This public presence could inspire additional venture capital and foster a virtuous cycle of innovation, investment and job creation across the province.
Why it Matters
Kardium’s $31.25‑million federal grant is a decisive vote of confidence in Canada’s medical‑device innovation pipeline. By enabling the firm to double its clean‑room capacity, the funding not only accelerates the production of a clinically superior atrial‑fibrillation treatment but also strengthens the country’s strategic autonomy in a critical health‑technology sector. The investment reinforces British Columbia’s standing as a leading centre for life‑sciences manufacturing, attracts further private capital, and creates high‑skill employment opportunities. In a broader context, this support underscores the government’s commitment to nurturing home‑grown breakthroughs that can compete globally, ensuring that Canadian patients benefit from cutting‑edge therapies while bolstering the nation’s economic resilience.
